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ABSTRACT: The introduction of fluoroalkyl groups into 
organic compounds can significantly alter 
pharmacological characteristics. One enabling but 
underexplored approach for the installation of 
fluoroalkyl groups is selective C(sp3)–H 
functionalization due to the ubiquity of C–H bonds in 
organic molecules. We have engineered heme enzymes 
that can insert fluoroalkyl carbene intermediates into -
amino C(sp3)–H bonds and enable enantiodivergent 
synthesis of fluoroalkyl-containing molecules. Using 
directed evolution, we engineered cytochrome P450 
enzymes to catalyze this abiological reaction under mild 
conditions with total turnovers (TTN) up to 4,070 and 
enantiomeric excess (ee) up to 99%. The iron-heme 
catalyst is fully genetically-encoded and configurable by 
directed evolution so that just a few mutations to the 
enzyme completely inverted product enantioselectivity. 
These catalysts provide a powerful method for synthesis 
of chiral organofluorine molecules that is currently not 
possible with small-molecule catalysts.
Fluoroalkyl groups are important bioisosteres in 
medicinal chemistry that can enhance the metabolic 
stability, lipophilicity, and bioavailability of drug 
molecules.1 Conversion of CH bonds into carbon-
fluoroalkyl bonds represents one of the most appealing 
strategies for fluoroalkyl group incorporation.2 Such 
methods are of high atom economy and provide efficient 
ways to obtain new organofluorine molecules via late-
stage functionalization of complex bioactive molecules.3 
Despite the synthetic appeal of this strategy, however, 
enantioselective C(sp3)H fluoroalkylation reactions are 
noticeably lacking. Major obstacles to development of 
transition-metal catalyzed CH fluoroalkylation 
reactions are the inherent challenges associated with 
carbon-fluoroalkyl bond cross-coupling pathways, such 
as slow oxidative addition of fluoroalkyl nucleophiles4 
and facile fluoride elimination of organometallic 
species.4b,5
A strategy involving insertion of fluoroalkylcarbene 
intermediates into C(sp3)H bonds could potentially 
circumvent these challenges. Although metal 
fluoroalkylcarbene intermediates have been utilized for a 
number of carbene transfer reactions,5b,6 their 
applications for CH functionalization have rarely been 
explored.7 Transition metal catalysts, including those 
based on rhodium8, iridium,9 copper,10 iron,11 and other 
metals,12 have been shown to catalyze carbene insertion 
into C(sp3)H bonds. Intermolecular stereoselective 
reactions, however, are typically constrained to 
dirhodium-based catalysts with carbene precursors 
bearing both electron-donating and electron-
withdrawing substituents at the carbene carbon (referred 
to as donor-acceptor carbene reagents).8a,12a The 
electron-donating group is required to attenuate the high 
reactivity of dirhodium-carbene intermediates and offers 
better stereo-control of the CH functionalization/CC 
bond forming step.13 Catalysts that can use acceptor-
only-type perfluorodiazoalkanes as carbene precursors 
for direct, enantioselective C(sp3)H fluoroalkylation 
have not been reported.
Our group recently disclosed iron-heme enzymes 
derived from cytochromes P450 that catalyze abiological 
carbene CH bond insertion reactions using several 
acceptor-only diazo compounds.14 Building on this 
effort, we now show that engineered cytochrome P450 
enzymes can adopt CH fluoroalkylation activity with 
high efficiency and enantioselectivity, achieving direct 
CH fluoroalkylation of substrates that contain -amino 
CH bonds. Given the high prevalence of amines in 
pharmaceuticals, this simple biocatalytic method 
provides an efficient route to molecular diversification 
through selective C–H functionalization.
To identify a suitable starting point for directed 
evolution of a CH fluoroalkylation enzyme, we first 
challenged a panel of 14 heme proteins in clarified 
Escherichia coli lysate with N-phenylpyrrolidine (1a) 
and 2,2,2-trifluoro-1-diazoethane (2) as model substrates 
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under anaerobic conditions (Table S1). Several proteins, 
including Rhodothermus marinus cyt c (Rma cyt c), 
engineered Rma NOD, and wild-type P450BM3 from 
Bacillus megaterium, exhibited trace catalytic activities. 
Reactions with only the heme cofactor (iron 
protoporphyrin IX) as the catalyst also delivered trace 
amounts of product 3a. Several serine-ligated 
cytochromes P450 (P411s),15 however, exhibited 
promising initial activity for the target 
trifluoroethylation reaction. The highest activity (1,250 
TTN) was obtained with P411-CH-C8. This P411ΔFAD 
variant, which comprises the heme and FMN but not the 
FAD domain of P450BM3, was originally engineered for 
carbene CH insertion with ethyl diazoacetate (EDA).14
-20
0
20
40
60
80
100
0
1000
2000
3000
4000
5000
6000
To
ta
lT
ur
no
ve
rN
um
be
r
ee
/%
-12%
28%
32%
80%
88%
98%
P411-CH-C8 FA-B3 FA-B7 FA-C4 FA-E3 P411-PFA*
*P411-PFA = P411-CH-C8 T327V L177M E70T R226T Y330V L401P
Figure 1. Directed evolution of P411 catalysts for 
C(sp3)H fluoroalkylation reaction. Experiments were 
performed using clarified E. coli lysate overexpressing the 
P411 variants, 10 mM 1a, 20 mM 2, 25 mM D-glucose, 5 
mg/mL sodium dithionite, GOx and 5 vol% EtOH in M9-N 
buffer at room temperature under anaerobic condition for 
12 h.
Although P411-CH-C8 exhibited high activity for the 
fluoroalkylation reaction between 1a and 2, the 
enantioselectivity of the resulting product 3a was poor 
(12% ee, (S)-enantiomer, Table S1). We therefore used 
directed evolution to increase enantioselectivity (Figure 
1). We first targeted several amino acid residues in the 
distal heme pocket for site-saturation mutagenesis and 
screened for variants with improved enantioselectivity. 
Many of the sites selected for mutagenesis were 
previously shown to affect activity and selectivity in 
abiological carbene- and nitrene-transfer reactions 
(Table S2). Although none of the mutants tested showed 
improvement in forming (S)-3a, we discovered that a 
T327V mutation inverted  enantioselectivity and yielded 
(R)-3a with 28% ee. With the T327V mutant (P411-FA-
B3) as the new parent, further rounds of site-saturation 
mutagenesis and recombination of beneficial mutations 
yielded variant FA-E3 with five mutations (T327V, 
E70T, L177M, R226T, and Y330V) compared to P411-
CH-C8. This variant exhibited 88% ee for (R)-3a.
We next surveyed residues in the enzyme’s proximal 
loop; residues in this region play an important role in 
regulating the oxidation activity of cytochromes P450.16 
Our lab and others have shown that mutations in this 
region also affect abiological carbene and nitrene 
transfer reactivities, mainly by tuning the electron-
donating properties of the heme proximal axial 
ligand.15,17 With FA-E3 as the parent, site-saturation 
mutagenesis on proximal loop residues and screening 
revealed the L401P mutation that further improved 
activity to 4,070 TTN and enantioselectivity to 98% ee 
(Figure 1). This final variant, named P411-PFA, 
contains six mutations from P411-CH-C8 (T327V, 
E70T, L177M, R226T, Y330V, and L401P, Figure S1).
N
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Figure 2. Substrate scope of P411-PFA-catalyzed C–H 
trifluoroethylation reaction. Absolute configuration of 3a 
was determined by X-ray crystallography.
With this laboratory-evolved CH fluoroalkylation 
enzyme in hand, we then explored its performance on a 
diverse set of substrates. As shown in Figure 2, P411-
PFA could install a trifluoroethyl group onto various N-
aryl pyrrolidine substrates by directly activating the α-
amino CH bonds. High activity and enantioselectivity 
were achieved for pyrrolidines containing a variety of N-
aryl and N-heteroaryl substituents. A range of functional 
groups including methoxy, halogen, ketone, and 
aldehyde were well tolerated. The tolerance to the p-
methoxylphenyl group (PMP) would enable the facile 
Page 2 of 6
ACS Paragon Plus Environment
Journal of the American Chemical Society
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
synthesis of other N-substituted pyrrolidines bearing a 
trifluoroethyl stereogenic center, as PMP is a well-
established protecting group for the nitrogen atom and 
can be removed under mild conditions.18 Furthermore, 
given the compatibility of our method with reactive 
functional groups like halogens and aldehydes, the 
application could be broadened further by harnessing 
these functionalities as reaction handles to access a 
diverse range of structural motifs through well-
established cross-coupling and condensation reactions.  
This enzymatic approach opens possibilities to access a 
broad range of chiral trifluoroethylated pyrrolidines, 
whose current construction methods require stepwise, 
successive radical cross coupling chemistry that is time-
consuming and not enantioselective.19
In addition to pyrrolidine-type substrates, this 
enzymatic method could also functionalize N,N-dialkyl 
anilines, which is another structural motif prevalent in 
pharmaceuticals. The enzyme is highly selective toward 
α-amino CH bonds. For instance, in compound 3k, the 
N-methyl is activated exclusively in the presence of 
weaker benzylic CH bonds. The preference for C−H 
bonds at α-amino positions over those at the benzylic 
and OMe (3b) positions might arise from the strong 
electron-donating properties of nitrogen, which makes α-
amino C−H bonds react more favorably with the 
electrophilic iron-carbene intermediates.8a,20 To further 
demonstrate synthetic utility, we performed this 
enzymatic reaction on preparative scale, where it 
proceeded smoothly and afforded the chiral 
trifluoroethylated compound 3a with 64% isolated yield 
and 98% ee (116 mg). We obtained the crystal structure 
of compound 3a, and the absolute configuration of the 
trifluoroethylated chiral center was determined to be R.
Alternate stereoisomers of a bioactive molecule can 
have drastically different biological effects and need to 
be evaluated individually during drug candidate 
screening.21 This necessitates the synthesis of all 
possible stereoisomers of a given molecule, preferably 
via stereo-divergent asymmetric catalysis.22 Thus we 
developed an enzyme catalyst that could perform the 
targeted CH trifluoroethylation with enantioselectivity 
opposite to that of P411-PFA. To find a suitable starting 
point for evolving an enzyme that exhibits reversed 
enantioselectivity, we first evaluated the catalytic 
performance on various substrates of all the variants 
along the evolution of P411-PFA. Early variant FA-B7 
exhibited moderate reversed enantioselectivity (24% ee 
for the (S) enantiomer) for functionalization of 
aldehyde-substituted N-aryl pyrrolidine substrate 1g. 
Further examination of variants derived from FA-B7 led 
to the discovery of a quadruple mutant of FA-B7 (T70E, 
V327T, G74P, Q437L, termed P411-PFA-(S)) that 
catalyzes the formation of (S)-3g with 92% ee (Figure 3, 
Figure S4). P411-PFA-(S) is a general catalyst for 
synthesis of the (S)-enantiomer of trifluoroethylated 
pyrrolidines, as demonstrated by its high activity and 
moderate-to-high (S)-enantioselectivity toward a variety 
of N-aryl and N-heteroaryl pyrrolidine substrates (Figure 
3). These results further highlight the facile 
configurability of the enzymatic system for delivering 
diverse chiral organofluorine molecules.
Figure 3. Enantiodivergent C(sp3)–H trifluoroethylation 
catalyzed by P411-PFA and P411-PFA-(S) and substrate 
scope of P411-PFA-(S).
Another advantage of this chemistry is its ability to 
install other fluoroalkyl groups via the same CH 
functionalization process. As a proof of concept, we 
challenged the protein catalysts with 2,2,3,3,3-
pentafluoro-1-diazopropane 4 as the carbene precursor. 
As shown in Figure 4, P411-PFA can use 4 to introduce 
pentafluoropropyl groups into the α-amino C–H bonds 
of both acyclic and cyclic amine substrates with 
excellent activity and enantioselectivity. We 
successfully obtained 59.1 mg of the enzymatic product 
5e. Intriguingly, subsequent X-ray crystallographic 
analysis showed that the pentafluoropropylation 
products obtained by P411-PFA exhibited an opposite 
absolute configuration to that of the trifluoroethylation 
ones. Although further investigation is needed to fully 
elucidate the origin of this inversion of absolute 
configuration, a potential cause is a conformational 
change of the corresponding fluoroalkylated heme-
carbene intermediates, which alters the orientation of the 
fluoroalkyl groups and reverts the configuration of the 
prochiral face accessed by the substrates for CH bond 
activation. This hypothesis is supported by the fact that 
carbene intermediates in heme proteins can adopt 
different conformations depending on their structural 
properties.6f,6g
Page 3 of 6
ACS Paragon Plus Environment
Journal of the American Chemical Society
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Figure 4. Substrate scope of P411-PFA-catalyzed C–H 
pentafluoropropylation. Absolute configuration of 5e was 
determined by X-ray crystallography.
In summary, we have developed a catalytic platform 
for insertion of fluoroalkyl-substituted carbenes into 
C(sp3)–H bonds with high activity and enantioselectivity 
under mild conditions. With directed evolution, the 
enantioselectivity of the enzymes can be tuned to 
achieve enantiodivergent synthesis of organofluorine 
compounds by this versatile carbene C–H insertion 
process. This work provides a powerful new approach 
for addition of fluorine-containing structural motifs 
prevalent in pharmaceuticals and further expands the 
reaction scope of new-to-nature enzymatic CH 
alkylation. We envision that the enzymes developed in 
this research will open up new avenues for synthesis of 
fluorinated bioactive molecules.
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